Amgen announced that the U.S. Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) and granted Priority Review for tezepelumab in the treatment of asthma. Tezepelumab is being developed by Amgen in collaboration with AstraZeneca.
- Read more about Tezepelumab Granted Priority Review By USFDA
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2021/tezepelumab-granted-priority-review-by-usfda
No comments:
Post a Comment